The Clinical TMS Society released the first results from its industry-wide TMS Outcomes Registry, reporting a 55% response rate and 31% remission rate across 50,000 patients treated in U.S. clinics over the past four years. The figures exceed remission rates commonly cited from industry-funded clinical trials, which have historically reported 25-30% remission.
The registry includes data from clinics using all FDA-cleared TMS devices and a mix of standard 10Hz, theta burst, and accelerated protocols. Outcomes are based on PHQ-9 scores collected at intake and end of treatment.
Response and remission rates were broadly similar across device manufacturers, with no statistically significant difference once case mix was adjusted for severity, prior treatment failure, and comorbidities. The strongest predictors of remission were younger age, fewer prior treatment failures, and completion of at least 30 sessions.
The registry will publish quarterly updates and is expected to be a key data source for ongoing payer policy decisions and for quality benchmarking across clinics. Participation is voluntary; the Society indicated it intends to push for broader participation as a condition of clinic certification.
Source
Reporting based on coverage from Clinical TMS Society. This article is editorial summary intended for general information; it is not medical advice.